Payment overview · 2025
General Payments
$234.78
11 reported records · 6 companies
Healthcare provider profile · identity verified
Miriam Brandon, MD
Allopathic & Osteopathic Physicians|Internal Medicine · POWELL, TN · NPI 1376587790
Verified facts
What the public records show
CMS Open Payments records show Miriam Brandon, MD received $234.78 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 61.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $143.66 | 61.2% | 6 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.50 | 11.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.36 | 7.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.57 | 7.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.14 | 6.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $13.55 | 5.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $234.78 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $143.66 | 6 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $27.50 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $18.36 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 55 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 98 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 85 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
84 | 21 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
55 | 55 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
85 | 71 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
98 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 664 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 438 | 116 |
| Atorvastatin Calcium | Atorvastatin Calcium | 371 | 92 |
| Lisinopril | Lisinopril | 279 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 258 | 74 |
| Omeprazole | Omeprazole | 255 | 66 |
| Gabapentin | Gabapentin | 225 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 160 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 146 | 46 |
| Losartan Potassium | Losartan Potassium | 139 | 37 |
| Simvastatin | Simvastatin | 133 | 36 |
| Trazodone Hcl | Trazodone Hcl | 112 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 32 |
| Metformin Hcl | Metformin Hcl | 107 | 25 |
| Montelukast Sodium | Montelukast Sodium | 100 | 28 |
| Ozempic | Semaglutide | 98 | 21 |
| Alprazolam | Alprazolam | 95 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 35 |
| Alendronate Sodium | Alendronate Sodium | 94 | 33 |
| Furosemide | Furosemide | 94 | 30 |
| Famotidine | Famotidine | 92 | 26 |
| Irbesartan | Irbesartan | 92 | 25 |
| Meloxicam | Meloxicam | 87 | 29 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 85 | 71 |
| Synthroid | Levothyroxine Sodium | 84 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 77 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 71 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 20 |
| Lovastatin | Lovastatin | 68 | 19 |
| Enalapril Maleate | Enalapril Maleate | 67 | 17 |
| Metformin Hcl Er | Metformin Hcl | 67 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 65 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 65 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 15 |
| Allopurinol | Allopurinol | 62 | 16 |
| Sertraline Hcl | Sertraline Hcl | 61 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 27 |
| Bupropion Xl | Bupropion Hcl | 56 | 14 |
| Eliquis | Apixaban | 56 | 14 |
| Ezetimibe | Ezetimibe | 56 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 24 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 55 | 55 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 54 | 14 |
| Tramadol Hcl | Tramadol Hcl | 54 | 16 |
| Clonidine Hcl | Clonidine Hcl | 51 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 14 |
| Potassium Chloride | Potassium Chloride | 51 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 43 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 49 | 34 |
| Donepezil Hcl | Donepezil Hcl | 48 | 11 |
| Spironolactone | Spironolactone | 48 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | suppressed |
| Glipizide Er | Glipizide | 46 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 45 | 11 |
| Estradiol | Estradiol | 42 | 13 |
| Benazepril Hcl | Benazepril Hcl | 41 | 12 |
| Jardiance | Empagliflozin | 41 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 41 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 39 | 19 |
| Valsartan | Valsartan | 39 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 35 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 34 | suppressed |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Methocarbamol | Methocarbamol | 31 | 18 |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 17 |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 18 |
| Pregabalin | Pregabalin | 27 | suppressed |
| Clonidine | Clonidine | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 17 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Wegovy | Semaglutide | 24 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 19 |
| Modafinil | Modafinil | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 12 |
| Fluconazole | Fluconazole | 18 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Dotti | Estradiol | 17 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 17 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 11 |
| Acyclovir | Acyclovir | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Cimetidine | Cimetidine | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 12 |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $234.78 · 11 records | ABBVIE INC. | AREXVY, ELUVIA, ETERNA, Ozempic, Rybelsus, SHINGRIX, VRAYLAR, Veozah | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error